IL2 and type 1 diabetes mellitus: The use of IL-2 to stimulate Treg-mediated immune regulation is a desirable alternative immunotherapy and early prevention strategy for T1D, according to the findings of a preclinical trial [39] and a phase I/II clinical trial [40].